How Often Does the GLP-1 Drug Albiglutide Cause Pancreatitis? An Expert Panel Reviewed Every Case

Independent pancreatitis adjudication committee (PAC) of gastroenterology and pancreatic disease experts prospectively reviewed all suspected acute pancreatitis cases from 8 HARMONY Phase III clinical trials. Cases were classified as definite, probable, possible, or unlikely pancreatitis, and relationship to study drug was assessed. Data came from 2,365 albiglutide patients and 2,530 comparator patients.

Whether GLP-1 drugs cause pancreatitis has been one of the most debated safety questions in diabetes medicine for over a decade. This rigorous independent review of nearly 5,000 patients provides some of the most carefully adjudicated data on the topic. While absolute rates were low, the signal is there — and it matters because millions of people now take GLP-1 drugs for diabetes and weight loss.

The pancreatitis question has followed the GLP-1 drug class since exenatide was first approved. This study, with its independent expert adjudication, is among the most methodologically rigorous assessments of the question. While albiglutide itself is no longer marketed, the findings are relevant to the entire GLP-1 class — including semaglutide and tirzepatide, which are now used by millions. The consistent finding across multiple GLP-1 drugs of a small but real pancreatitis signal means that monitoring for this complication remains clinically important.

The number of pancreatitis events was small (11 adjudicated cases), limiting statistical power for definitive conclusions. The placebo group (486 patients) was relatively small compared to active treatment groups. Albiglutide has since been withdrawn from the market (for commercial, not safety, reasons), so these data are most relevant as part of the broader GLP-1 class safety picture. The study could not determine whether pancreatitis risk is dose- or duration-dependent.